European Commission approves Xarelto for new indication

Germany-based Bayer has obtained a significant approval by the European authorities, which have given the green light to Xarelto (rivaroxaban) to prevent thrombosis in patients with coronary artery disease (CAD) and periphery artery disease (PAD). The first country where Xarelto is set to be made available for the new indication is Germany, where it is already approved for 6 more indications. Xarelto is probably the most important drug by the Leverkusen-based group, with revenues over €3.3bn.

(Source: Handelsblatt)